Amyloid-Journal of Protein Folding Disorders

Papers
(The TQCC of Amyloid-Journal of Protein Folding Disorders is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration228
Changes in the amyloid editorial board members and in editor positions210
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies95
A second case of liraglutide-type localised amyloidosis81
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study63
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey40
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases35
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis33
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange28
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging27
Survey of amyloidosis cases among different free-living wild and zoo animals24
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy21
A novel transthyretin variant p.Val114Glu (Val94Glu) in an Italian patient with mixed phenotype hereditary transthyretin amyloidosis19
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains18
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition18
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis17
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy16
Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis16
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis16
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay15
Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies15
Alterations in multi-layer strain in AL amyloidosis14
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)14
Identification of epidermal growth factor-containing fibulin-like extracellular matrix protein 1-derived amyloid deposition in a rhesus macaque13
Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice12
Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis12
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis12
Management of AL amyloidosis in 2021+11
Left atrioventricular coupling index assessed with three-dimensional echocardiography: a prognostic marker of short-term outcomes in light-chain cardiac amyloidosis11
Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody11
Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study10
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage10
Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China10
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures9
Brain MRI in patients with V30M hereditary transthyretin amyloidosis9
Utilization and tolerance of beta-blockers among patients with AL amyloidosis9
Abnormal electrochemical skin conductance values in patients with AA amyloidosis8
Refining prognostication in systemic AL amyloidosis: limited value of dFLC8
Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis8
Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant8
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee8
Correction8
Monitoring of cardiac transthyretin amyloid load by [99mTc]DPD scintigraphy: is it the end of the semi-quantitative evaluation?8
Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation8
A rare occurrence and near miss! Should a TTR gene test be routinely performed for suspected ATTR-cardiomyopathy?8
Incidence and predictors of sudden death in patients with cardiac amyloidosis7
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines7
Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours7
Complete remission after patisiran treatment in a patient with nephrotic syndrome secondary to hereditary transthyretin amyloidosis (ATTR)7
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis7
Prognostic impact of cardiac resynchronization therapy in wild-type transthyretin amyloid cardiomyopathy7
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution7
Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies6
Heterogeneity in families with ATTRV30M amyloidosis: a historical and longitudinal Portuguese case study impact for genetic counselling6
Neuropathy progression in hereditary transthyretin amyloidosis (ATTRv) patients after liver transplantation6
Altered connectivity of central autonomic network: effects of dysautonomia in hereditary transthyretin amyloidosis with polyneuropathy6
Detection of ATTR aggregates in the plasma of polyneuropathic patients with ATTR-V30M amyloidosis6
A family with extremely early onset ATTRv amyloidosis and an F44S mutation in China6
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study6
Epidemiology of hereditary transthyretin amyloidosis in the northernmost region of Sweden: a retrospective cohort study6
Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis6
0.087341070175171